Quick Answer
X4 Pharmaceuticals, Inc reported Total Revenue of $35.11 million for fiscal year 2025.
X4 Pharmaceuticals, Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $35.11M +1273.2% |
$2.56M | $0.00 | $0.00 | $0.00 -100.0% |
$3.00M |
| Revenue (ASC 606) | $35.11M +1273.2% |
$2.56M | $0.00 | $0.00 | $0.00 -100.0% |
$3.00M |
| Net Income | -$79.20M -111.5% |
-$37.45M +63.0% |
-$101.17M -7.8% |
-$93.87M -5.8% |
-$88.70M -42.8% |
-$62.13M -17.7% |
| Diluted EPS | -$1.87 +66.5% |
-$5.59 +67.3% |
-$17.07 -1023.0% |
-$1.52 +61.9% |
-$3.99 -29.1% |
-$3.09 |
| Total Assets | $290.46M +98.3% |
$146.45M -0.6% |
$147.26M -5.4% |
$155.59M +32.8% |
$117.18M -4.6% |
$122.87M -23.5% |
| Cash and Equivalents | $217.05M +289.7% |
$55.70M -43.9% |
$99.22M -18.5% |
$121.72M +48.8% |
$81.79M +3.9% |
$78.71M -37.6% |
| Stockholders Equity | $186.29M +741.1% |
$22.15M -56.7% |
$51.10M -31.0% |
$74.05M +15.0% |
$64.41M -11.5% |
$72.80M -43.7% |
| R&D Expense | $72.72M -10.9% |
$81.64M +13.4% |
$72.02M +17.9% |
$61.06M +20.6% |
$50.65M +20.8% |
$41.93M +39.0% |
| Operating Income | -$86.88M -138.7% |
-$36.40M +66.1% |
-$107.52M -22.8% |
-$87.57M -2.9% |
-$85.11M -42.1% |
-$59.87M -15.8% |
| Shares Outstanding | 90.91M +1495.4% |
5.70M -96.6% |
167.43M +37.6% |
121.67M +332.6% |
28.13M +72.5% |
16.31M +1.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.76M | +215.2% | -10.5% |
| Revenue (ASC 606) | September 30, 2025 | $1.76M | +215.2% | -10.5% |
| Net Income | September 30, 2025 | -$29.82M | +18.8% | -15.8% |
| Diluted EPS | September 30, 2025 | -$0.69 | +87.4% | +80.1% |
| Total Assets | September 30, 2025 | $163.56M | -8.2% | +55.5% |
| Cash and Equivalents | September 30, 2025 | $69.63M | -28.5% | +77.5% |
| Stockholders Equity | September 30, 2025 | $61.62M | +3.4% | +1451.7% |
| R&D Expense | September 30, 2025 | $17.34M | -9.6% | -5.5% |
| Operating Income | September 30, 2025 | -$27.51M | +20.3% | -4.9% |
| Shares Outstanding | September 30, 2025 | 25.15M | -85.1% | +215.9% |
- X4 Pharmaceuticals, Inc reported Total Revenue of $35.11 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +1273.2% in Total Revenue compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Revenue (ASC 606) of $35.11 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +1273.2% in Revenue (ASC 606) compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Net Income of -$79.20 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed a decrease of -111.5% in Net Income compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Diluted EPS of $1.87 per share (loss) for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +66.5% in Diluted EPS compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Total Assets of $290.46 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +98.3% in Total Assets compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Cash and Equivalents of $217.05 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +289.7% in Cash and Equivalents compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Stockholders Equity of $186.29 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +741.1% in Stockholders Equity compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported R&D Expense of $72.72 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed a decrease of -10.9% in R&D Expense compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Operating Income of -$86.88 million for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed a decrease of -138.7% in Operating Income compared to the prior fiscal year.
- X4 Pharmaceuticals, Inc reported Shares Outstanding of 90.91 million shares for fiscal year 2025.
- X4 Pharmaceuticals, Inc showed an increase of +1495.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: